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Abstract 
Human rhinovirus (HRV) infections are the most prevalent cause of the common 
cold but may also induce a predisposition for bacterial infections as well as 
exacerbations of asthma. The pathogenic mechanisms of HRV infections leading 
to such complications are still poorly understood.  
Dendritic cells (DC) are the main professional antigen presenting cells of the 
immune system. With the help of viral pattern recognition receptors (VPRR) DC 
can recognize evolutionary highly conserved molecular patterns of viruses. Once 
activated, the resulting mature DC are capable of inducing adaptive immune 
responses. 
HRV, are small, icosahedral, nonenveloped (+)-strand single-stranded RNA 
(ssRNA) viruses. We have previously shown that HRV14, a member of the major 
group rhinoviruses, specifically down-modulates the accessory function of 
monocyte-derived-DC (DC). HRV14-treated DC do not mature and show a 
strongly diminished T-cell stimulatory capacity due to the upregulation of 
inhibitory surface molecules.  
HRV do not replicate in DC. However, DC are well equipped with different single-
stranded viral RNA (ssvRNA) detecting VPRR. Therefore, we wondered whether 
the genomic RNA of HRV alone, as a potential danger signal, has the capacity to 
induce DC maturation. 
This study shows that HRV ssvRNA is recognized by DC, causing a strong Type 
I interferon (IFN) response. A profound IFN induction was also observed in a 
luciferase reporter assay using RIG-I-transfected HEK cells, identifying RIG-I as 
a potential VPRR for HRV RNA. However, in DC, in contrast to HEK cells, 
ssvRNA failed to induce NFκB activation, which is required for proper maturation 
induction. Furthermore, markers of maturation like the surface molecule CD83 
were absent, and the proinflammatory cytokines TNFα, IL-12 and IL-6 were not 
produced. In addition, HRV ssvRNA failed to induce an increased T-cell 
stimulatory capacity in an allo-mixed leukocyte reaction. Therefore, ssvRNA of 
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HRV is only a semi-danger signal for DC: Despite recognition, ssvRNA fails to 
induce proper DC maturation. 
Zusammenfassung 
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Zusammenfassung 
Infektionen durch humane Rhinoviren (HRV) sind die häufigste Ursache für 
Erkältungen. Sie bedingen aber auch eine Prädisposition für bakterielle 
Infektionen sowie Verschlimmerungen von Asthmaanfällen. Die pathogenen 
Mechanismen von HRV Infektionen, die jene Komplikationen verursachen, 
werden hingegen schlecht verstanden. 
Dendritische Zellen (DC) sind die wichtigsten Antigen-präsentierenden Zellen 
(APC) des Immunsystems. Mit Hilfe von viral pattern recognition Rezeptoren 
(VPRR) können DC evolutionär hoch konservierte molekulare Muster von Viren 
erkennen. Die nach solcher Aktivierung resultierenden reifen DC besitzen die 
Fähigkeit, eine adaptive Immunantwort einzuleiten. 
HRV sind kleine, ikosahedrische, nicht-Membran-umhüllte (+)-Strang 
Einzelstrang RNS (ssRNA) Viren. Wir haben kürzlich gezeigt, dass HRV14, ein 
Mitglied der major group HRV, die akzessorische Funktion von DC 
herunterreguliert. HRV14 behandelte DC reifen nicht und weisen durch die 
Expression inhibitorischer Oberflächenmoleküle eine stark herabgesetzte 
Kapazität zur T-Zell Proliferationsstimulation auf. 
HRV replizieren in DC nicht. DC sind aber mit unterschiedlichen VPRR 
ausgestattet, die virale ssRNA (vssRNA) erkennen. Aus diesem Grund war 
unsere Fragestellung, ob die genomische RNS von HRV alleine - als potentielles 
danger signal - die Kapazität hat, DC Reifung zu induzieren. 
Diese Studie zeigt, dass HRV ssvRNA durch DC erkannt wird, was zu einer 
starken Typ 1 Interferon (IFN) Antwort führt. Diese IFN Induktion wurde auch in 
einem Luciferase Reporter Assay unter Verwendung von RIG-I transfizierten 
HEK Zellen gefunden. Dieses Ergebnis identifiziert RIG-I als potentiellen VPRR 
für HRV RNA. Dennoch konnten wir in DC, im Gegensatz zu HEK Zellen, keine 
NFκB Aktivierung, die für die DC Reifung wesentlich ist, durch ssvRNA 
feststellen. Weiters wurden typische Reifungsmarker wie CD83, sowie die 
Freisetzung der proinflammatorischen Cytokine TNFα, IL-12 und IL6 nicht 
induziert. Letzlich konnte ssvRNA in einer allo-mixed leukocyte reaction keine 
Zusammenfassung 
  
 
erhöhte T-Zell stimulatorische Kapazität von DC bewirken. HRV ssvRNA ist also 
nur ein semi-danger Signal für DC: Trotz Erkennung, induziert ssvRNA keine DC 
Reifung. 
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Abbreviations 
APC  antigen presenting cell 
ARD  ankyrin repeat domain 
CD  cluster of differentiation 
CLR  C-type lectin receptor 
cSMAC central supramolecular complex 
Ctrl.  control 
DC  dendritic cell 
cDC  conventional dendritic cells 
dephospho. dephosphorylated 
dsRNA double-stranded ribonucleic acid 
eIF  eukaryotic initiation factor 
GM-CSF granulocyte-macrophage colony stimulating factor 
HEK  human embryonic kidney cells 
HRV  human rhinovirus 
ICAM  intercellular adhesion molecule 
IFN  interferon 
IκB  inhibitor of κ-B 
IKK  IκB kinase 
IL  interleukin 
IRES  internal ribosome entry site 
IRF  interferon regulatory factor 
IS  ummunological synapse 
ISRE  interferon signaling response element 
JAK  Janus kinase 
LDL  low density lipoprotein 
LPS  lipopolysaccharide 
mAb  monoclonal antibody 
MDA-5 melanoma-differentiation-associated gene 5 
md-DC monocyte-derived dendritic cell 
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MHC  major histocompatibility complex 
MLR  mixed leukocyte reaction 
MNC  mononuclear cells 
NFκB  nuclear factor κ-B 
NK  natural killer cells 
mRNA messenger ribonucleic acid 
NFW  nuclease free water 
ORF  open reading frame 
PAMP  pathogen-associated molecular pattern 
PBMC  peripheral blood mononuclear cells 
pDC  plasmacytoid dendritic cells 
pI:C  polyriboinosinic:polyribocytidylic acid 
PKR  protein kinase R 
phosho. phosphorylated 
pSMAC peripheral supramolecular complex 
PRR  pattern recognition receptor 
RHD  rel homology domain 
RIG-I  retinoic acid-inducible gene I 
RT  room temperature 
Sn  sialoadhesin 
ssRNA single-stranded ribonucleic acid 
ssvRNA single-stranded viral ribonucleic acid 
STAT  signal transducer and activator of transcription 
Th  T helper cell 
TGF  tumor growth factor 
TLR  Toll-like receptor 
TNF  tumor necrosis factor 
Treg  T regulatory cells 
UTR  untranslated region 
VP  viral protein 
VPRR  viral pattern recognition receptor 
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1. Introduction  
1.1. DC and their functions 
 
The human immune system is constituted by an innate as well as an adaptive 
component. The innate immune system is the first line of host defense against 
pathogens, whereas the adaptive immune system is important for removing 
pathogens during later phases of infection. Only concerted actions of both 
systems allow an efficient host defense response against invading pathogens. 
Adaptive immunity is charaterized by the capability to rearrange immunoglobulin 
genes to produce a large repertoir of antigen-specific receptors and the 
establishment of an immunological memory. The innate immune system, on the 
other hand, expresses limited numbers of germ-line encoded PRR, which have 
evolved to recognize highly conserved molecular patterns, thereby providing a 
kind of inherited memory function.1 
DC link these two parts of the immune system by capturing and presenting 
antigens resulting in the initiation of adaptive immunity.2 
1.1.1. DC have immunogenic properties 
DC are a heterogenous population of bone-marrow-derived immune cells. 
Multiple subtypes of DC with different life span and immune function have been 
identified. In the absence of infection, the steady state, plasmacytoid DC (pDC), 
which are specialized on the production of high amounts of Type I IFN, and 
conventional DC (cDC) are found in the nonlymphoid tissues, in the circulation, 
and the lymphoid tissues (thymus, spleen, lymph nodes). Owing to their 
heterogenicity, also the resident cDC in lymphoid tissues consist of 
phenotypically different subsets. According to their tissue localization, cDC can 
be classified into skin DC in the epidermis (Langerhans cells) or dermal DC in the 
dermis; lymphoid-tissue associated DC; mucosal tissue-associated DC; and 
interstitial DC located, for instance, in liver and lungs.3 
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Soon after the discovery of DC by Steinman et al. in 1972 ,4 it became clear that 
this cell type plays a central immunogenic role as professional antigen presenting 
cell (APC). In an experimental system for graft rejection, the mixed leukocyte 
reaction (MLR), DC were found to be 100 times more potent in inducing 
allogeneic T-cell proliferation compared to other cell types like macrophages, B-
cells or monocytes.5,6 More importantly DC are the most versatile APC because 
they are the only cell type capable of inducing a primary immune response, 
resulting in the proliferation of naive T-cells and thereby the induction of an 
adaptive immune response. This finding defines DC as key players in 
immunogenicity, which is the capacity of inducing an immune response. 7-9 
 
1.1.2.The maturation model 
 
 
 
 
Fig. 1 The maturation model (adapted from 10) 
 
 
DC activation 
DC are present as immature precursors either in the peripheral tissues, blood or 
secondary lymphoid organs. The T-cell stimulatory function of DC is however not 
a constitutive property.11 It is rather primed by inflammatory cytokines like TNF, 
IL-1, or interferons produced during infection. However, for the induction of DC 
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maturation exogenous stimuli like microbial products (f.i. LPS, CpG, dsRNA) are 
required additionally.12,13 DC sense these danger signals by pattern recognition 
receptors (PRR) which are specialized on detecting a broad spectrum of 
pathogen-associated molecular patterns (PAMP). Once receiving these 
activation signals a maturation program is started, which co-ordinates many 
phenotypical and functional changes, involving antigen capture and presentation, 
migration, costimulation, production of T-cell polarizing cytokines and 
prolongation of DC life-span (see Fig. 1).14,15  
 
Migration to the local lymph nodes 
During maturation DC lose their responsiveness to inflammatory chemokines like 
CCL3, CCL5, or CCL20 through receptor downregulation or desensitization. On 
the other hand, the upregulation of CCR7, the lymph node-homing chemokine 
receptor, allows the response to homeostatic chemokines (CCL19, CCL21). As a 
consequence, those DC residing in the periphery or blood start migrating to the 
T-cell areas of local draining lymph nodes.16 Furthermore, in the presence of GM-
CSF, which levels rise during inflammation, monocytes residing in the blood can 
start to differentiate into monocyte-derived DC (md-DC) upon migration into the 
peripheral tissue.17 
 
Decreased phagocytic capacity and enhanced antigen presentation 
Immature DC show high levels of constitutive macropinocytosis and 
phagocytosis, which allow them to constantly sample the surrounding area for 
pathogen entry. Furthermore, they express endocytic receptors for pathogens 
like the mannose receptor, DEC-205, or DC-SIGN allowing their specific uptake. 
In contrast, mature DC, activated via PRR signaling, shut off their high endocytic 
rates and switch to antigen processing and presentation. The synthesis and 
transport of MHCII molecules ensures that DC can present degraded 
extracellular antigens in a MHCII-antigen complex to the antigen-specific T-cell 
receptor (TCR) on naive CD4+ T-cells. Furthermore, DC are capable of cross-
presenting degraded exogenous antigens. This is achieved by releasing these 
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antigens into the cytosol, where they are degraded by the proteasome. After re-
uptake into the phagosome, they can assemble with MHCI, which normally only 
presents intracellular endogenous antigens, and travel to the plasma membrane. 
These complexes can then interact with specific TCR on CD8+ T-cell. The low 
affinity interaction of MHC-antigen complexes with specific TCR is also refered to 
as signal 1 of antigen presentation. 9,18 
 
Costimulation and the immunological synapse (IS) 
In naive T-cells low doses of antigen presented by MHC molecules on DC are 
not sufficient to trigger TCR signaling. For this purpose, costimulatory 
interactions (refered to as signal 2) between DC and T-cell are required. In order 
to allow sustained receptor stimulation and signal amplification, multiple DC and 
T-cell interactions are required.9  
The original model, based on experiments with B-cell - T-cell interactions, 
proposed that an immunological synapse (IS) was needed to achieve this goal: 
The IS is a multimolecular complex which results from a polarized interaction 
between T-cell and APC. It organizes the recruitment and segregation of cell-
surface receptors and intracellular adaptor and signaling molecules.19 
The IS is formed of an outer ring, the peripheral supramolecular activation 
complex (pSMAC), allowing adhesion molecule interactions between ICAM-1 (on 
DC) and LFA-1 (on T-cells) providing cell-cell attachment and a central region, 
the central SMAC (cSMAC), enriched in MHC-antigen (DC) and TCR (T-cell) 
complexes. In addition, as a consequence of maturation, DC also express the 
costimulatory molecules CD80 and CD86 in this inner ring. These molecules bind 
to the T-cell surface molecule CD28 thereby boosting TCR signaling. 20 
Recently the model of a static IS required for T-cell activation by DC in contrast 
to B-cells has been challenged: It appears that DC induced TCR signaling occurs 
rather in peripheral microclusters allowing MHC-antigen-TCR and CD80/CD86-
CD28 interactions. These microclusters, constituting a multifocal IS, are formed 
before the cSMAC is assembled. The latter, however, seems to act in TCR 
recycling rather than T-cell activation. This is also supported by the presence of 
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CD45, a potent phosphatase of effector molecules, in the cSMAC.21 The cSMAC 
may also be required for secondary inhibitory signaling pathways which are 
upregulated after TCR triggering, including ICOS and CTLA-4 activation by the 
DC ligands ICOS-L and CD80 / 86.22 
In support of this dynamic IS model in DC, segregation of CD80/86-CD28 
interactions from MHC-antigen-TCR complexes was shown to enhance 
costimulation. This seems to be achieved by a dynamic regulation of the DC 
actin cytoskeleton, which acts to form selective barriers in the plasma membrane 
of DC. This mechanism may also prevent MHC-antigen-TCR clusters from 
migrating into the cSMAC region, thereby delaying inactivation of the signal 
cascade induced by MHC-antigen-TCR interactions. Taken together, T-cell 
activation by DC is achieved by sustained microcluster formation, which involves 
multiple MHC-antigen-TCR and costimulatory CD80/86-CD28 interactions.21  
 
Recently it was found that costimulation is more complex than originally 
anticipated. Apart from the classical CD28-CD80/86 interaction, additional 
costimulatory interactions are required to allow effective long-lasting T-cell 
responses or the generation of memory T-cells. These additional interactions are 
carried out by members of the tumor-necrosis factor receptor (TNFR) family: The 
mainly inducible receptor / ligand pairs are thought to modulate the quantity, 
quality and duration of immune responses. Receptor / ligand pairs crucial for 
additional costimulation include CD40 ligand (CD40L) / CD40, OX40- OX40L, 4-
1BB / 4-1BBL, CD27 / CD70, and herpes-virus entry mediator (HVEM) / LIGHT.23 
Notably CD40L expressed by activated T-cells is a key regulator of T-cell 
costimulation since interaction with increased levels of CD40 on mature DC 
upregulates the expression of costimulatory molecules like CD80/86, 4-1BBL, 
OX40L and CD70,24 enhances antigen presentation and IL-12 production.25 
On T-cells CD27 and HVEM are constitutively expressed, whereas the 
expression of OX40, 4-1BB, and CD40L is induced during T-cell activation. 
Noteably, HVEM is downregulated by T-cell activation and its ligand LIGHT on 
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DC is also no longer expressed by mature DC indicating a role during early 
activation of T-cells and APC.23 
To summarize, members of the CD28-B7 costimulatory family cannot fully 
account for effective long-lasting T-cell responses. However, all costimulatory 
TNFR-family molecules are potentially available at the time of antigen encounter 
or within several days after. According to a recent model they control the 
absolute number of effector T-cells which accumulate during a primary response, 
thereby determining whether a protective T-cell response can occur.23,24 
1.1.3 DC tune T-cell responses  
DC, as the main APC inducing primary immune responses, do not only start 
adaptive immunity, they also shape T-cell polarity. The capability of DC to fine-
tune T-cell responses allows DC to induce appropriate adaptive immune 
responses adjusted to the kind of invading pathogen.26 
Specific T-cell responses are mainly achieved by the selective release of 
polarizing cytokines by DC. IL-12 induces a Th1 response required for fighting 
intracellular pathogens like viruses and bacteria whereas IL-4 release causes 
differentiation into Th2 cells, which are critically involved in immune responses 
against helminths and extracellular toxins.27 Furthermore, TGFβ and IL-2 induces 
regulatory T-cells, which are essential for maintaining peripheral immune 
tolerance, and TGFβ in combination with IL-6 induce Th17 polarization. These 
cells have been shown to be involved in autoimmune diseases.28,29  
1.1.4. DC are involved in tolerogenicity 
There is strong experimental evidence that DC are also key players in the 
induction and maintainance of peripheral tolerance. It seems that in the steady 
state, which means in the absence of deliberate exposure to maturation signals, 
most DC fail to deliver adequate costimulatory signals which can tolerize 
peripheral CD4+ and CD8+ T-cells by inducing deletion, anergy or regulation. 
Thereby, DC keep immune responses in check and help to block the 
development of autoimmune diseases.30,31 For instance, immature human DC 
pulsed with influenza matrix protein failed to induce CD8+ T-cell effector 
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functions monitored after immunization in contrast to mature antigen-pulsed 
DC.32 Furthermore, T-cell tolerance may be induced by targeting resting DC with 
antigen in the absence of adjuvant causing T-cell unresposiveness. 33  
The term maturation was originally applied to DC to refer to the acquisition of 
immunogenicitiy. However, also DC expressing substantial levels of 
costimulatory molecules and other maturation markers may be tolerogenic rather 
than immunogenic. Ultimately, the distinction between an immunogenic and a 
tolerogenic DC might be in subtle quantitative differences in the expression of 
various known maturation markers34, or even in DC longevity.35 
1.1.5. DC influence other immune cells 
In addition to their function as APC, activated DC may also affect cell types other 
than T-cells. DC can release high amounts of IL-12, IL-18, and IFNα during 
infections. These cytokines do not only activate NK cells 36 but also induce B-cell 
differentiation into plasma cells required for antibody production.37,38 
 
1.2. Recognition of pathogens by PRR 
 
DC, among other cells of the immune system, are equipped with a repertoir of 
evolutionary highly conserved proteins, specialized on the recognition of specific 
PAMP like carbohydrates, lipids or ribonucleases. These proteins called PRR, 
allow the sensitive detection of bacterial, fungal or viral pathogens before 
pathogen spread and intervention by the adaptive immune system occur.1 
PRR differ according to their protein family and cellular localization. The Toll-like 
receptors (TLR), which are type I integral membrane glycoproteins, are localized 
at the plasma membrane as well as in the endosomes,39,40 whereas the NOD-like 
receptors, detectors of bacterial components41, as well as the DExD/H box RNA 
helicases42 are found exclusively in the cytoplasm. Additionally DC express C-
type lectin receptors (CLR) on their plasma membrane. These receptors are, in 
contrast to the other PRR, specialized on antigen binding and uptake. They 
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primarily act by modifiying PRR signaling induced by other PRR. Antigen uptake 
by CLRs alone rather causes tolerance than DC activation.43 
PRR have distinct expression patterns which has important implications on the 
type of pattern that is recognized by a certain DC subtype.39 Furthermore, 
expression of PRR can be additionally modified by the activation or tissue 
localization of the DC allowing tissue-specific responses to microbial 
stimulation.44 
Finally there is increasing evidence that different PRR co-operate in the induction 
of DC maturation, enableing DC to fine-tune their reponse. For instance, CLR like 
the mannose receptor or the β-glucan receptors (f.i. dectin-1) participate in the 
uptake of microbial components, which can cause DC activation after PAMP 
recognition by cytoplasmic PRR.44 The vast majority of experimental evidence 
comes, however, from TLR co-operation. For instance, combined TLR ligand 
stimulation of DC may cause synergistic induction of TNF, IL-1β, IL-6, IL-10, IL-
12, and IL-23 compared to single agonist stimulation.45,46 On the contrary, 
cytokine production can also be negatively regulated by simultaneous signaling 
through certain TLR. TLR2 activation can, for instance, block TLR3 or TLR4 
ligand induced IL-12p35 expression by the increased production of IL-10.47 The 
molecular mechanisms underlying co-operative activation of PRR signaling are 
just starting to be deciphered. However, knowledge about multiple PRR 
activations required for host resistance to pathogens has important implications 
for developing vaccination and immunotherapy strategies against infectious 
diseases. Recent studies highlighted the effectiveness of simultaneously applied 
TLR ligands as potent adjuvants.48,49 
1.2.1. Viral pattern recognition receptors (VPRR) 
DC activation is induced by viral PAMP recognized by VPRR belonging to two 
protein families: The TLR (TLR2, 4, 7, 8, 9) and the DExD/H box RNA helicases 
(MDA-5, RIG-I). Initially, VPRR were believed to become exclusively activated in 
a virus replication dependent way. MDA-5 and TLR3, for instance, respond to 
dsRNA replication intermediates. Recent findings, however, emphasize the 
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presence of VPRR which are activated by ssRNA or viral glycoproteins in the 
absence of a productive infection (TLR7/8, RIG-I, or TLR2,4) (for details see 
table 1). 40,50 
Furthermore, DC are also equipped with the dsRNA binding proteins protein 
kinase R (PKR) and 2`,5`-oligoadenylate synthetase, which are upregulated in an 
IFN-dependent fashion. Therefore, they are involved in amplifying the activation 
process induced by other VPRR.51 In addition, DC also express CLR, like 
mannose receptor, DEC-205 and DC-SIGN, which are in contrast to other PRR, 
specialized on antigen binding and uptake. They primarily act by modifiying PRR 
signaling. Antigen uptake by CLRs alone does not cause DC activation.43 
Since most VPRR are specialized on recognizing RNA, a molecular pattern not 
exclusively confined to the viral system, cellular compartimentalization of VPRR 
is a key determinant in foreign and self RNA discrimination. The endosomal 
located TLR are only challenged with RNA (of viral origin) under physiological 
conditions. This enables the cells to discriminate between foreign and self 
RNA.52,53  
On the other hand, in the cytoplasm where cellular mRNA are abundant, foreign 
and self RNA distinction is mainly based on the presence of uncapped 5`-ends 
and unmodified nucleotides, a hallmark of many viral genomes. The uncapped 
5`-end is usually absent in cellular mRNAs, which are capped 54, or is masked by 
bound cellular proteins.55,56 Furthermore, cellular RNAs usually undergo 
conversion to contain modified nucleotides, which decrease the RNA`s VPRR 
stimulatory capacity.57  
In addition, secondary structures of ssvRNA genomes as well as non-methylated 
CpG DNA from DNA viruses may be specifically recognized.1,40,58 
As with PRR in general, also for VPRR there are cell-type and DC subtype 
specific expression patterns, which has functional consequences: in vitro 
generated md-DC in contrast to pDC, for instance, neither express TLR9 nor 
TLR7, which renders them incapable of detecting unmethylated CpG DNA and 
makes TLR7 usage impossible (also see table 1).39 
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DC subsets may also differ according to their uptake mechanisms. pDC 
compared to md-DC retain endocytosed components in their endosomes for a 
longer time period, which may potentiate TLR signaling.59,60 
 
Name of 
the 
receptor 
Protein family Expressed 
by  
Cellular 
localization 
Recognized PAMP Artificially 
activated 
by 
TLR2 Toll-like 
receptors 
md-DC plasma 
membrane 
viral glycoproteins  
(f.i. measles virus) 
zymosan 
TLR3 Toll-like 
receptors 
md-DC endosome dsRNA pI:C 
TLR4 Toll-like 
receptors 
md-DC plasma 
membrane 
viral glycoproteins  
(f.i. RSV, MMTV) 
LPS 
TLR7 Toll-like 
receptors 
pDC endosome ssvRNA, synthetic 
ssRNA rich in GU, 
siRNA53,61,62 
R-848, 3M-
002 63,64 
TLR8 Toll-like 
receptors 
md-DC endosome ssvRNA, synthetic 
ssRNA rich in GU 
53,62 
R-848, 3M-
002 63,64 
TLR9 Toll-like 
receptors 
pDC endosome CpG DNA 65 CpG oligo-
nucleotides 
66 
RIG-I DExD/H box 
RNA helicases 
pDC, md-
DC 
cytoplasm 5`-triphosphorylated 
ssRNA/dsRNA, 
secondary structures 
in ssvRNA 57,58,67 
see 
recognized 
PAMP 
MDA-5 DExD/H box 
RNA helicases 
pDC, md-
DC 
cytoplasm dsRNA replication 
intermediates 68 
transfected 
pI:C 69 
Table 1: Overview about VPRR which differ according to their protein family, expression, 
localization and recognized PAMP 1,39,40 
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1.2.2. VPRR Signaling 
Despite the presence of several VPRR, VPRR activation by their specific PAMP 
has evolved to apply highly conserved signaling transduction pathways which 
converge on the activation of type I IFN as well as the transcription factor family 
nuclear factor κB (NFκB) (Fig.2). 1,40 
 
 
 
 
Fig. 2 Signal transduction after VPRR activation (adapted from 70) 
 
 
Type I IFN activation and function 
The IFN response is an early host defense mechanism, which occurs prior to an 
immune response and is required for the establishment of an antiviral state (see 
below). Although IFN actions are pleiotropic, their antiviral activity has been 
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studied the most. In humans all Type I IFN including IFNα, IFNβ, and IFNω have 
antiviral activity. Humans express just one IFNβ and IFNω, but 13 different 
isoforms of IFNα.51 
In the host cell, Type I IFN induce the activation of interferon regulatory factors 
(IRF). These proteins bind to conserved consensus sequences, the so called IFN 
signaling response elements (ISRE), thereby inducing the expression of a broad 
repertoire of antiviral proteins. These proteins exert their function by blocking 
viral replication and thereby induce an antiviral state.51 
The best characterized known IFN-inducible gene products with antiviral activity 
are the Mx GTPases. The Mx1 gene was originally identified in inbred mice 
which showed an extraordinary high degree of resistance against influenza A 
virus infections. Mx proteins are inducible by IFNα/β but not by IFNγ. In humans 
two Mx GTPases, MxA and MxB, are expressed, but only MxA has an intrinsic 
antiviral activity. MxA is located in the cytoplasm and acts by blocking viral 
nucleocapsid transport into the nucleus, a process which involves GTPase 
activity.51 
Another Type I IFN-induced enzyme with antiviral activity is APOBEC, a 
deaminase, which impairs retrovirus replication by introducing additional 
mutations.40 
Yet, the RNA-dependent PKR is another example of an IFN-induced protein. 
PKR activation initiated by binding of RNA with ds character, induces a multitude 
of downstream effects. For instance, PKR is responsible for eukaryotic initiation 
factor 2α (eIF-2α) and inhibitor of κB (IκB) phosphorylation, which causes a block 
in mRNA translation and NFκB activation, respectively.51 
Furthermore, Type I IFN also induce a “2-5A response“ leading to degradation of 
RNA. This involves two enzymes, 2`,5`-oligoadenylate synthetase (OAS) and 
RNase L. dsRNA activated OAS catalyzes the synthesis of oligoadenylates 
(abbreviated 2-5A), which in turn activate RNase L, a potent endoribonuclease. 
RNase L then starts to degrade both viral and cellular RNAs. The degradation of 
self-RNA was recently shown to amplify antiviral innate immunity by inducing 
IFNβ expression.71 
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Type I IFN can also exert their action in an autocrine as well as paracrine 
fashion. All released isoforms bind to the Type I IFN receptors IFNAR1 and 
IFNAR2. The activated receptors form heterodimers eliciting a Janus kinase 
(JAK) – signal transducer and activator of transcription (STAT) mediated signal 
transduction pathway which amplifies Type I IFN production. On the other hand, 
secreted Type I IFN harbor a protective antiviral effect on other cell types, limiting 
viral replication and spread.51 Furthermore, they signal danger to NK cells, 
amplify DC maturation and facilitate the induction of adaptive immune 
responses.72  
 
NFκB activation and function  
The family of NFκB proteins is a central mediator of inflammatory responses and 
immune function. The vast majority of the inflammatory gene expression program 
is NFκB dependent. Therefore, these dimeric transcription factors control 
hundreds of genes. Examples of proteins relevant for DC maturation controlled 
by NFκB activity include the cytokines IL-1β, IL-6, IL-10, and IL-12 or the surface 
molecules CD40, CD83, and CD86.73 
In vertebrates the highly conserved NFκB transcription factors are constituted by 
homo- and heterodimers composed of five different proteins: p50, p52, c-Rel, 
RelA (also called p65) and RelB. All of them have a Rel Homology Domain 
(RHD) at their N-terminus which is responsible for DNA binding, dimerization, 
inhibitor binding, and nuclear localization.74 
In resting cell, NFκB is usually located in the cytoplasm. NFκB nuclear 
localization and DNA binding activity is tightly controlled by the family of IκB 
proteins. These proteins are a subfamily of the large ankyrin repeat domain 
(ARD) containing superfamily. The ARD domain is used to mask the nuclear 
localization signal of NFκB dimers thereby hindering nuclear import of these 
transcription factors. Cellular stimulation causing PRR activation results in 
specific phosphorylation, ubiquitination and proteasome-mediated proteolysis of 
IκB proteins which frees NFκB dimers. This specific activation of NFκB is 
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mediated by different types of IκB kinases (IKK). The canonical pathway is 
induced by IKKβ and utilizes IκBα, IκBβ, and IκBε as inhibitors. The non-
canonical pathway is activated by IKKα and utilizes the p52 precursor protein 
p100, whose C-terminal domain can function like an IκB protein to sequester 
NFκB dimers in an inactive state.74,75 
NFκB activation causes translocation into the nucleus where NFκB assembles 
with other transcription and co-factors. DNA binding of these complexes is 
mediated via the RHD domain to highly degenerate consensus sequences in the 
promoter of NFκB target genes. Upon these many target genes also the IκB 
genes are found. This means that IκB metabolism is dynamically regulated not 
only by stimulus induced degradation but also by feedback re-synthesis.74,75 
Because of their closely interwoven interactions the small network of IKK, IκB, 
and NFκB proteins has been termed the NFκB signaling module.76,77 
1.3. Human rhinoviruses (HRV) 
 
HRV infections are the most prevalent cause of the common cold but may also 
induce a predisposition for bacterial infections as well as exacerbations of 
asthma. The pathogenic mechanisms of HRV infections leading to such 
complications are still poorly understood. 78-80 
HRV, family members of the Picornaviridae, are small, icosahedral, 
nonenveloped (+)-strand ssRNA viruses. So far more than 100 serotypes of 
HRV, which are classified according to their receptor binding specificities, are 
known: The vast majority of HRV belong to the major group rhinoviruses, which 
bind to human ICAM-1 81,82, whereas minor group rhinoviruses make use of the 
low density lipoprotein receptor family,83 Notably HRV are host specific 
exclusively infecting humans. 
1.3.1. HRV cell entry and structure of the viral genome 
Viral cell entry is mediated rather by receptor-mediated endocytosis than by 
direct transfer of the viral RNA into the cytosol.84,85 Once inside the cell, viral 
protein translation can start from the positive strand genomic RNA, which has a 
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highly conserved structure: Genes encoding viral capsid proteins are followed by 
genes for non-structural  proteins. This coding region is flanked by untranslated 
regions (UTRs) at the 5` and 3` end. These UTRs form extensive secondary 
structures which are required for translation and viral replication.86 
 
Fig.3 The genome of HRV (adapted from 87) 
VP = viral protein, NTR = non-translated region, extensive secondary structures at the 5`NTR 
represent IRES, AAAn = polyA tail,  
 
 
 
A unique feature of the picornavirus genomic RNA is the presence of a covalently 
attached viral protein, VPg, at the 5` end as well as a polyA tail at the 3` end 
(Fig.3). Since HRV lack a cap-structure at the 5`end of the RNA, viral translation 
is initiated at an internal ribosome entry site (IRES) located upstream of the 
single open reading frame (ORF).88 Therefore, viral proteins are synthesized by a 
cap-independent mechanism leading to the formation of a single polyprotein, 
which is cleaved into smaller entities mainly by the virus encoded proteinases 
3Cpro and 2Apro.89,90 Both proteinases have also been shown to cleave cellular 
proteins.91 During a productive infection this causes cleavage of the eukaryotic 
initiation factors eIF4GI and eIF4GII, which leads to  “host cell shutoff“. This 
means that translation of the capped cellular mRNAs is blocked during the 
initiation step, whereas un-capped viral RNA is translated efficiently via a cap-
independent mechanism. This enables the virus to use the host cell for its own 
purposes since viral in contrast to cellular protein synthesis is unaffected by this 
cleavage. 92,93 
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1.3.2. HRV – modulators of the immune system  
HRV mainly infect the ciliated epithelial cells of the upper respiratory tract. 
However, histological examinations of virus-infected nasal epithelium 
demonstrated no cytopathic effects. Instead, the release of proinflammatory 
mediators during HRV infections could be observed. These soluble factors are 
considered to induce proliferation, chemotaxis, and activation of inflammatory 
cells, which causes an amplification of the inflammatory process. 
Despite the limiting coding capacity of HRV, these viruses have evolved 
sophisticated ways of evading immune activation and slowing down immune 
responses.  
Neutralizing antibodies, for instance, are produced relatively late during HRV 
infection. Currently there are also no reports about a CD8+ cytotoxic T-cell 
response, which is usually central in fighting non-cytopathic viruses, during HRV 
infections. 94 
On the other hand, major group HRV actively manipulate mononuclear 
phagocyte adhesiveness, thereby possibly retaining these cells at the site of 
inflammation and hindering emigration to the lymphoid tissues. 95 
Furthermore, HRV has been shown to increase IL-10 release by monocytes, 
which has been hypothesized to decrease the local inflammatory reaction.96 
In addition, major group HRV also manipulate DC, by inducing the upregulation 
of the inhibitory surface molecules, B7-H1 and sialoadhesin (Sn):97 
B7-H1 is a family member of the B7 molecule family. It was originally identified as 
costimulatory receptor promoting T-cell proliferation. However, it was shown 
recently that B7-H1 is an accessory molecule which exerts its inhibitory effects 
through the PD-1 receptor on T-cells. Furthermore, it is critically involved in T-cell 
anergy induction in IL-10 treated DC. Although mature DC also express high 
levels of B7-H1, its inhibitory function seems to be overwhelmed by abundantly 
expressed costimulatory molecules like CD80 and CD86. Interestingly B7-H1 is 
also expressed by a variety of tissue cells. Thereby, its expression is believed to 
be important for maintaining peripheral tolerance.98,99 
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Sn, on the other hand, is a member of the sialic acid binding lectin family of I-type 
lectins which preferentially bind to sialylated carbohydrate structures.100 Sn is a 
macrophage marker which is not expressed by monocytes, lymphocytes and 
DC.101 Recently CD43 has been described as the receptor for Sn on T-cells. 
CD43 is usually removed from the IS to the distal pole of T-cells to allow DC-T-
cell interaction during antigen presentation. Since HRV14 treated DC show high 
levels of Sn, its interaction with CD43 may play a significant role in disturbing 
proper IS formation.97 
Taken together HRV treated DC may induce a deep anergic state in T-cells by 
the upregulation of inhibitory surface molecules.97 
On the basis of these findings, it has been hypothesized that the unique 
functional modulation of immune cells by HRV may cause adverse effects on 
local immunity, thereby predisposing affected individuals to secondary 
infections.94 
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2. Aims of this work 
 
DC, as the main players linking innate and adaptive immunity, are well equipped 
with VPRR to detect viral entry and consequently prevent virus replication and 
spread. A recent study has added up to our understanding of how HRV 
manipulate the accessory function of these cells.97 However, the initial steps of 
HRV recognition and the influence of these processes on DC maturation are 
unknown. 
HRV do not replicate in immune cells, in contrast to epithelial or endothelial 
cells.96,102,103 Therefore, this work focused on the effects of ssvRNA from major 
and minor group HRV on DC. In particular, we were aiming to find out whether 
HRV ssvRNA, as a potential danger signal, can induce DC maturation 
independent from its serotype as a consequence of VPRR activation. For this 
purpose, we intended to study early signal transduction pathways induced by 
HRV genomic RNA, as well as the outcoming immune stimulatory capacity of 
these DC. 
In addition, luciferase reporter assays in HEK cells were performed to identify a 
potential receptor for HRV RNA. 
 
Fig. 4 Aims of this study 
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3. Results 
 
3.1. HRV genomic RNA is recognized by DC independent of its 
phosphorylation status 
 
In contrast to many cell lines, HRV do not replicate in immune cells (see Fig.5). 
96,102 Therefore, we wondered whether the ssvRNA on its own can induce DC 
maturation, and the intact virus has evolved some kind of evasion strategy to 
interfere with this recognition process, thereby blocking DC maturation. 
 
Fig.5 HRV14 does not replicate in DC 
RNA from HRV14 treated Hela cells (A) or DC (B) was isolated after the indicated time points. 
cDNA was generated and used for the real time PCR reaction. Test results were normalized to 
the message of the housekeeping gene G3DPH. The results shown represent the fold inductions 
of the HRV14 positive strand compared to the 30 minutes incubation step. One representative 
experiment out of two is shown. Mean values of duplicate determinations +- standard deviation 
are shown. 
 
To get hold of HRV genomic RNA, ssvRNA was purified by two methods: First 
the genomic RNA was directly isolated from a viral suspension (Fig.6 A), but due 
to low yield, we switched to in vitro transcription, which provided high yields of 
good quality RNA. This RNA was derived from an in vitro transcription plasmid 
A 
 
B 
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encoding the whole genomic RNA including the untranslated regions and the 
polyA tail (Fig.6 B, C). 
 
 
Fig.6 Purification of HRV genomic RNA 
HRV2/14 genomic RNA was isolated either from a viral suspension using Tri reagent (A) or by in 
vitro transcription from linearized T7 promoter in vitro transcription plasmids encoding full lenght 
genomic RNA of HRV2/14 including the untranslated regions and the poly A tail (B). After DNA 
digestion and purification, the in vitro transcription reaction gave rise to high yields of degradation 
free, highly pure viral RNA as shown on the agarose gel (C). Part of the RNA was 
dephosphorylated by calf intestine alkaline phosphatase to generate RNA lacking the 5`-
triphosphate which may be sensed by the VPRR RIG-I. 57,67 This RNA species resembles better 
the natural occuring genomic RNA, which lacks a 5`-triphosphate and is capped by the viral 
protein Vpg (see left panel at the bottom). As a control for the in vitro transcription and 
dephosphorylation reaction the control (ctrl.) RNA for elongation factor 1α from xenopus was 
treated exactly the same as the viral RNA. 
 
In nature HRV genomic RNA is capped at the 5`-end by the viral protein VPg, 
thereby blocking recognition by the VPRR RIG-I. Since in vitro transcribed RNA 
has a triphosphate instead of a cap at the 5`-end, this potential danger signal can 
be effectively removed by calf intestine alkaline phosphatase.57,67 (also see Fig.6) 
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To control the efficiency of this dephosphorylation process, a control RNA from 
Xenopus (ctrl RNA)  was synthesized and processed identically to the viral RNA.  
 
Fig.7 HRV genomic RNA induces strong MxA expression independent from its 
phosphorylation status 
(A)  DC were stimulated either with LPS (100ng/ml), R-848 (2 µg/ml), HRV14 (5 TCID50), 
Lipofectamine (0,5 µl) or medium. Cytoplasmic MxA expression was assessed after two days of 
incubation by FACS analysis. The thin line in the histograms represent binding of the isotype 
control antibody, whereas the thick line shows the reactivity of the monoclonal anti-MxA antibody 
with the stimulated DC. 
(B) DC were transfected with ctrl, HRV2 or HRV14 RNA at different molarities using 
lipofectamine. Part of the RNA had been dephosphorylated by calf intestine alkaline phosphatase 
after in vitro transcription. MxA expression was detected as described in (A). 
Staining from one representative experiment out of at least 4 experiments with different donors is 
shown. 
 
Since a Type I IFN response is a hallmark of virus recognition 40, we performed 
cytoplasmic FACS stainings of MxA, a type I IFN induced protein,104 as a read 
out system. As shown in Fig.7 B DC either transfected with in vitro transcribed 
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ctrl RNA or HRV RNA strongly upregulated MxA expression, comparable to 
HRV14 or LPS treated cells (Fig.7 A). In contrast, dephoshorylated HRV RNA 
was still recognized by DC, whereas dephosphorylated ctrl RNA was only 
inducing MxA expression at high concentrations. On the other hand, for RNA 
amounts of 0,086 pmol and below, DC recognized only HRV RNA independ of its 
phosphorylation status, whereas the ctrl RNA was only sensed as a danger 
signal in its phosphorylated form. 
 
 
Fig.8  Dephosphorylated RNA has a strongly diminished stimulatory capacity on RIG-I 
HEK cells were transiently transfected with plasmids encoding RIG-I and ß-galactosidase along 
with an ISRE reporter plasmid from which luciferase protein is synthesized upon RIG-I activation. 
Cells were either mock treated or transfected with different amounts of phosphorylated / 
dephosphorylated in vitro transcribed ctrl RNA (1,68 pmol, 0,336 pmol, 0,067 pmol) or transfectin 
alone. Luciferase activity was measured by a luminometer and the ratio between this value and 
the ß-galactosidase activity was calculated. Shown are the relative mean values of duplicate 
measurements as fold inductions of mock treated cells +- standard deviation. 
 
The efficiency of the dephosphorylation reaction was also controlled with an 
independent experiment. In this luciferase reporter assay HEK cells transiently 
transfected with RIG-I and an IFN signaling induced luciferase reporter were 
either transfected with phosphorylated or dephosphorylated ctrl RNA. In this 
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assay, as expected, only phosphorylated ctrl RNA was causing a strong IFN 
response, whereas this induction was significantly diminished after 
dephosphorylation (Fig.8). 
 
3.2. RIG-I is a potential VPRR for HRV RNA 
 
Surprisingly, the HRV14 RNA was also specifically upregulating the IFN 
response in RIG-I transfected HEK cells, independent of its phosphorylation 
status (Fig.9 A). These data fit to the results of the cytoplasmic FACS stainings, 
however, they suggest in addition that RIG-I is a potential VPRR for HRV 
recognition.  
Furthermore, it should be noted that similiar results were obtained from a 
luciferase reporter assay using a NFκB luciferase reporter: The ctrl RNA showed 
increased luciferase activity due to RIG-I activation only in its phosphorylated 
form. The HRV RNA, however, also activated NFκB signaling in its 
dephosphorylated form (Fig.9 B). These findings are in accordance with reports 
from the literature stating that activated RIG-I induces both IFN and NFκB 
signaling.40,42 
From these results we concluded that the dephosphorylation reaction had been 
performed efficiently and that other features of HRV RNA than its 5`-
phosphorylation status are crucial for recognition. Furthermore, we could show 
that both 5`-phosphorylated ctrl RNA and dephosphorylated HRV14 RNA are 
specifically recognized by RIG-I. This recognition process involved both IFN and 
NFκB signaling in RIG-I transfected HEK cells. 
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Fig.9 RIG-I is a potential VPRR for HRV RNA 
HEK cells were transiently transfected with plasmids encoding RIG-I and ß-galactosidase along 
with an ISRE (A) or NFκB (B) reporter plasmid from which luciferase protein is synthesized upon 
RIG-I activation. Cells were either mock treated, transfected with 1ug pIC, transfected with 
different amounts of phosphorylated / dephosphorylated in vitro transcribed HRV14 RNA (0,43 
pmol, 0,086 pmol, 0,0172 pmol) (A), equimolar amounts of phosphorylated / dephosphorylated in 
vitro transcribed ctrl RNA or dephosphorylated HRV14 RNA (0,43 pmol each) (B) or transfectin 
alone. Luciferase activity was measured by a luminometer and the ratio between this value and 
the ß-galactosidase activity was calculated. Shown are the relative mean values of duplicate 
measurements as fold inductions of mock treated cells +- standard deviation. 
 
3.3. HRV genomic RNA neither induces NFκB activation nor 
inhibits its activation by maturation stimuli 
 
The results from the HEK luciferase assay suggested that RIG-I can specifically 
detect HRV14 RNA, which induces both IFN and NFκB signaling. Therefore, we 
wanted to confirm the second hallmark intimately linked to viral pattern 
recognition by assessing NFκB activation in DC.  
Activation of DC with maturation stimuli like LPS or the TLR7/8 agonist R-848 
causes degradation of IκB, a NFκB inhibitor, which can be easily assessed by 
Western blot analysis. Degradation of IkB starts early after stimulation and is 
characterized by a feedback loop causing enhanced IκB production.74 Although 
we could find this type of response after LPS or R-848 stimulation, we were 
A  B 
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neither able to detect IκB degradation after treatment with HRV14 nor after 
transfection with its genomic RNA (see Fig.10 A). This is reminiscent of an 
electrophoretic mobility shift assay (EMSA) performed with the intact virus: over a 
time range of 9 hours, no NFκB binding to the NFκB consensus sequence could 
be detected (Fig.10 B). 
 
 
 
 
Fig.10 Both HRV14 and its RNA fail to induce NFκB activation in DC 
(A) DC were stimulated with either R-848 (2 µg/ml), LPS (100 ng/ml), HRV14 (5 TCID50) or 
transfected with 0,086 pmol HRV14 RNA. Cells were harvested after the indicated time points 
and subjected to SDS-PAGE. Specific signals for IκB-α were detected by Westernblot analysis. 
Loading controls were determined with an antibody against total p38 after stripping the 
membranes. One representative experiment out of three is shown. 
(B) Nuclear extracts from DC stimulated either with medium, LPS (100 ng/ml) or HRV14 (5 
TCID50) were purified after the indicated time points and incubated with radiolabelled NFκB 
consensus sequence. Specific binding to this sequence causes a shift during the EMSA 
(electrophoretic mobility shift assay) experiment. NFκB = specific binding of NFκB to its 
consensus sequence, NS= nonspecific binding, free Pr.= free radiolabelled primers 
Since HRV are positive strand RNA viruses, viral proteins can be translated from 
the genome once having entered the cytosol. Although there is a lack of 
replication, low concentrations of proteins with inhibitory functions on the NFκB 
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pathway may be present. To exclude that HRV14 has evolved a NFκB blocking 
mechanism, DC were pretreated with the virus for 1h to allow viral entry and then 
stimulated with known inducers of the NFκB pathway and DC maturation. As 
shown in Fig.11 HRV14 neither blocks TLR3 nor TLR8 mediated IκB 
degradation, thereby rendering it unlikely that HRV14 is actively blocking NFκB 
activation in DC. 
Taken together, despite a strong Type I IFN induced MxA expression in HRV 
RNA transfected and HRV14 treated DC, the second hallmark of viral pattern 
recognition, namely NFκB activation, was absent in DC which is in sharp contrast 
to the situation in HEK cells. However, the missing NFκB activation in DC was 
not a consequence of active viral inhibition. 
 
 
 
 
 
 
 
 
 
 
Fig.11 HRV14 is not actively blocking IκB degradation induced by TLR agonists 
DC were either left untreated or were pre-incubated with HRV14 (5 TCID50) for 1 hour prior to 
stimulation with either pI:C or R-848 (both 2 µg/ml). Cells were harvested after the indicated time 
points and subjected to SDS-PAGE. Specific signals for IκB-α were detected by Westernblot 
analysis. Loading controls were determined with an antibody against total p38 after stripping the 
membranes.  
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Fig.12 HRV RNA transfected DC lack CD83 upregulation, whereas CD86 and inhibitory 
surface markers are induced 
The expression pattern of the surface molecules CD83, CD86, B7-H1 and Sn on DC was 
compared to the presence of cytoplasmic MxA after two days of stimulation. Antibodies 
recognizing surface molecules or cytoplasmic MxA (after permeabilization) were visualized by an 
Oregon Green-conjugated goat anti-mouse IgG antibody and detected by FACS analysis. Grey 
histograms represent the negative controls (non-binding mAb VIAP), whereas the thick lines 
show the specific binding of the respective mAb. 
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3.4. HRV genomic RNA fails to induce proper upregulation of the 
DC maturation marker CD83 
 
Although the presence of high numbers of maturation markers on the surface of 
DC is not exclusively an indicator for immunogenicity, it is however a pre-
exquisite.14 Maturation markers which are typically upregulated during maturation 
are CD83 and CD86. The expression of both surface proteins was clearly 
increased upon LPS stimulation as shown by FACS analysis. Although CD86 
expression was also induced by HRV14 treatment as well as transfection with 
ssvRNA, for these stimuli CD83 remained at the level of unstimulated cells 
(Fig.12). 
 
3.5. Transfection with HRV ssvRNA induces the enhanced 
expression of inhibitory surface molecules 
 
The ability of DC to deliver signal 2 to activate T-cells depends on the delicate 
balance of costimulatory as well as inhibitory surface molecules. Therefore, we 
also assessed the expression of the latter after DC stimulation.  
We have previously shown that HRV14 in contrast to HRV2 treatment of DC 
induces the expression of B7-H1 and Sn.97 For this reason, it was surprising to 
find that ssvRNA from both HRV serotypes iduced the expression of these 
inhibitory molecules (Fig.12). Furthermore, the upregulation of Sn strongly 
correlated with the MxA inducing potential of the stimulus. (compare MxA and Sn 
levels of HRV2 treated with HRV14 treated DC in Fig.12) 
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3.6. HRV ssvRNA transfected DC are poor producers of TNFα, IL-
6, IL-12, and IL-10 
 
During antigen presentation a defined cocktail of cytokines is required for the 
proper induction and fine-tuning of an adaptive immune response. The presence 
of cytokines released by DC upon stimulation therefore provides important 
information about the functional capability of these cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.13 HRV RNA neither induces the release of proinflammatory cytokines nor of IL-10 
The supernatants of stimulated DC were analyzed for their content of released cytokines after two 
days of culture with the indicated stimuli. TNFα, IL-6, IL12-p40, and IL-10 concentrations were 
determined by Luminex, whereas IFNα levels were assessed by ELISA. TNFα, IL-6, and IL-
12p40 concentrations are depicted on a log scale. 
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Whereas typical maturation inducers like LPS, pI:C and R-848 boosted the 
release of TNFα, IL-6, and IL-12p40, neither HRV nor its genomic RNA managed 
to do so. On the other hand, we could also not observe virus induced release of 
the anti-inflammatory cytokine IL-10 (Fig.13). 
This secretion profile was in sharp contrast to the release of IFNα measured by 
ELISA: HRV14 treated DC secreted relative high amounts of IFNα, and also 
HRV14 / 2  ssvRNA transfected DC were found to release IFNα (Fig.13). 
It should be noted that transfection with RNA did not increase cell death 
compared to lipofectamine treated cells (Fig.14). 
 
Fig.14 Transfection with Lipofectamine complexed RNA does not increase cell death in DC 
DC treated with medium (mock), LPS (0,1 µg/ml), HRV14/2 (5 TCID50) or transfected with 0,086 
pmol of HRV14 / HRV2 / ctrl RNA complexed to Lipofectamine or Lipofectamine alone were 
incubated for 2 days. Cell death was monitored by adding propidium iodide to DC prior to FACS 
analysis. The proportion of dead cells for each condition is expressed as a percentage at the right 
corner. 
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3.7. HRV ssvRNA transfected DC show a different T-cell 
stimulatory capacity compared to LPS or HRV-treated DC 
 
Maturation inducers like LPS typically induce an enhanced T-cell stimulatory 
capacity in DC compared to mock treated DC in an allo-mixed leukocyte reaction 
(MLR) (Fig.15). This capacity is evident at different DC - T-cell ratios and has 
been extensively used as an in vitro model system for testing DC capability of 
inducing an adaptive immune response after stimulation. 
 
 
Fig.15 DC transfected with HRV14 RNA show no enhanced T-cell stimulatory capacity 
Purified T-cells were stimulated with graded numbers of allogeneic DC inoculated with either 
HRV14 (5 TCID50) or transfected with HRV14 RNA (0,086 pmol) for 48h. As controls allogeneic 
DC transfected with ctrl RNA (0,086 pmol) or Lipofectamine as well as mock or LPS (100 ng/ml) 
treated DC were included. Proliferation of T-cells was monitored on day 5 of co-culture by adding 
methyl-3H-TdR followed by measuring its incorporation 18h later. The results of one 
representative experiment of three independent experiments is depicted. Shown are the relative 
mean values of triplet measurements +- standard deviation. 
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In contrast to LPS stimulated DC, HRV14-treated DC showed a strongly reduced 
T-cell stimulatory capacity as we have previously published.97 DC transfected 
with HRV14 ssvRNA showed, however, neither an enhanced nor a diminished T-
cell stimulatory capacity. The observed T-cell proliferation was rather comparable 
to mock or lipofectamine treated DC. Similiar results were also obtained with ctrl 
RNA transfected DC. 
 
Taken together, transfection of DC with HRV ssvRNA does not recapitulate 
treatment with the intact HRV14, because these cells show no reduced T-cell 
proliferation in an allo-MLR. Consequently, as previously postulated,97 signaling 
events downstream of ICAM-1 could be responsible for this discrepancy. 
Furthermore, our results support the idea that neither major nor minor group HRV 
genomic RNA, despite recognition and a resulting prominent Type I IFN 
response, has the potential to induce DC maturation.  
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4. Discussion 
 
For a long time, it was thought that viruses are only sensed by DC after 
replication. However, the finding that the VPRR TLR7/8 as well RIG-I detect 
ssRNA in a replication independent manner,40 shed more light on the 
sophisticated alternative virus detection mechanisms evolved by DC. 
In the past years, the major goal concerning VPRR activation in DC was to 
identify the PAMPs recognized by these receptors. Most experiments were done 
in the murine immune system. As a consequnce data about signal transduction 
and receptor activation were primarily based on studies with (knock out) mice or 
cell-lines.  
Recently, the identification of ssRNA as a potential agonist for TLR and DExH/D 
helicase signaling, has caused many research groups to focus on the immune 
stimulatory role of RNA: For instance, transfections of murine DC with GU-rich or 
viral ssRNA were shown to induce strong IFNα responses as well as the release 
of proinflammatory cytokines.53,57,61,67 Furthermore, transfections of DC with 
tumor derived RNA or immunostimulatory RNA oligonucleotides were shown to 
induce DC maturation.105,106 
In contrast, little is known about VPRR activation in human DC, especially in 
monocyte-derived-DC. Some studies showed that transfection of this cell type 
with mRNA encoding viral proteins or tumor antigens can induce DC 
maturation.107,108 However, so far there are no reports dealing with the question 
whether these cells can be functionally matured by ssvRNA transfection. –
However, it should be considered that md-DC are routinely used in DC-based 
cancer therapy trials.109 Therefore, data adding up to a more detailed view about 
activation of this cell type will be beneficial. 
Furthermore, we have previously shown that HRV14, a member of the major 
group rhinoviruses, specifically down-modulates the accessory function of DC: 
HRV14-treated DC do not become mature and show a strongly diminished T-cell 
stimulatory capacity due to the upregulation of inhibitory surface molecules.97 
Since DC are equipped with different ssvRNA detecting VPRR, we wondered 
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whether the genomic RNA of HRV14 alone, as a potential danger signal, has the 
capacity to induce DC maturation. 
In this study, we show that DC transfected with HRV14 ssvRNA react to this 
stimulation by a profound increase in cytoplasmic MxA, an IFN induced antiviral 
protein.104 Since similar results were obtained independent of the ssvRNA`s 
phosphorylation status, a PAMP other than the presence or absence of a 
triphosphate at the 5`end seems to play a role for recognition. Identical results 
found for HRV2 ssvRNA also show that the recognition process is independent 
from the receptor binding specificities of the HRV serotype. This is in contrast to 
the situation when DC are treated with intact HRV: Here only HRV14 induced a 
strong MxA induction. Therefore, PAMP involved in IFN induction are possibly 
highly conserved structures common to different HRV serotypes, for instance the 
non-translated regions (NTR) at the 3`or 5`-end of the genome.86 This idea is 
supported by a recent finding that conserved secondary structures in the NTR of 
the ssRNA genome of hepatitis C virus are specifically recognized by RIG-I.58 
Since a type I IFN response is a hallmark of VPRR activation and often 
discussed as a consequence of NFκB activation, it was surprising to find this 
second hallmark missing after either transfecting DC with ssvRNA or treating 
them with HRV14. However, a recent report claims that Type I IFN production is 
possible even in the absence of NFκB isoforms, thereby providing an explanation 
for this discrepancy.110 Furthermore, we have also shown that the missing NFκB 
activation is not a consequence of active viral interference, which is a major 
concern when dealing with positive strand viruses.111 
Given the fact, that for all known VPRR, activation of NFκB as a consequence of 
receptor activation has been described,1 it is puzzling not being able to see NFκB 
activation in DC after ssvRNA transfection. There are several possible 
explanations for this phenomenon: First, VPRR signal transduction has been 
mainly studied in murine immune cells or cell-lines. Therefore, these pathways 
may operate differently in human DC. Second, a yet unidentified RNA binding 
receptor specialized on IFN induction rather than known VPRR could be 
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activated by ssvRNA in DC. And finally, it is also possible that NFκB activation 
was occuring below the detection limit of the method used.  
The lack of NFκB activation, which has been known as a master switch of 
cytokine gene regulation for a long time, probably also entails the missing 
upregulation of the maturation marker CD83 as well as the lacking release of the 
proinflammatory cytokines TNFα, IL-12, and IL-6, all of which are known to be 
transcribed from NFκB regulated genes, in ssvRNA transfected DC. 
On the other hand, we were surprised to find, that the ssvRNA on its own can 
induce the expression of the inhibitory molecules B7-H1 and Sn in DC. Former 
studies indicated that the HRV14 receptor ICAM-1 was responsible for this 
phenomenon, since HRV2 treated DC failed to induce their expression.97 
However, as shown here, transfected HRV2 ssvRNA can also very effectively 
induce upregulation of both molecules in contrast to the intact virus. This 
phenomenon may be explained by a low LDL receptor expression on DC which 
makes entry of the HRV2 ssvRNA difficult if treated with the intact virus, thereby 
avoiding RNA detection. In addition, the strong correlation between MxA 
induction and Sn is in line with previous experimental data showing that the 
ICAM-1 specific antibody RR1/1 did not trigger Sn expression97 possibly due to 
the missing IFN response.  
Finally, it was not unexpected to find that HRV ssvRNA transfected DC exhibit no 
functionally mature phenotype in an allo-MLR. However, the observed low 
capacity to induce T-cell proliferation, was still not as profound as for HRV14-
treated DC. As we have shown previously, similar low capacities for the induction 
of T-cell proliferation were obtained with HRV14- or UV-treated HRV14 (which 
was still capable to bind to DC) DC.97 Therefore, we believe that signaling via 
ICAM-1 rather than signals derived from HRV ssvRNA might be critically involved 
in the downregulation of the T-cell stimulatory function of DC. 
The profound IFN response after HRV14 treatment or ssvRNA transfection, 
shows that the genomic RNA of HRV is specifically recognized by DC. -Studies 
with MDA-5 knock out mice have led to the hypothesis that MDA-5 was important 
for recognizing picornaviruses.69 Furthermore, it has been reported that TLR3 
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mediates antiviral activity against HRV in human bronchial epithelial cells.103 
However, activation of both VPRR requires viral replication, which is absent in 
DC treated with HRV. Therefore, it is more likely that HRV are recognized by a 
ssRNA binding receptor like TLR8 or RIG-I. 
The results of our luciferase reporter assay show that HRV RNA can indeed be 
specifically recognized by RIG-I, which can activate IFN as well as NFκB 
signaling in HEK cells transiently transfected with this VPRR. This finding is in 
contrast to the situation in DC, where we could not detect any NFκB activation. It 
is tempting to speculate about cell-type specific differences in signaling between 
HEK cells and DC. Furthermore, it should be noted that the HRV RNA still had 
some residual replication capacity in HEK cells in contrast to DC. This low 
concentration of HRV dsRNA may account for NFκB activation in HEK cells and 
might suggest that the presence of dsRNA is required for NFκB activation but is 
dispensable for IFN signaling. This idea would be in contrast to the common 
model, which describes activated VPRR receptors as potent inducers of IFN and 
NFκB signaling.1,42 However, it is in accordance with preliminary data showing 
that DC transfected with in vitro transcribed phosphorylated ctrl RNA showed no 
IκB degradation inspite of a prominent MxA response (data not shown). This 
observation was made although phosphorylated RNA is a well known activation 
stimulus for RIG-I.57,67  
So far, we were not able to find a similiar response after treatment of RIG-I 
transfected HEK cells with HRV14 compared to after transfection with HRV14 
RNA. (data not shown) A possible explanation might be that the concentration of 
virus used was too low to activate the reporter. However, higher concentrations 
of virus would have overriden the protective effect of the anti-apoptotic 
compound zVAD, which was recently shown to also block HRV replication.112  
In the future, it will be crucial to perform additional luciferase reporter assays with 
replication deficient HRV RNA in RIG-I or TLR8 / MDA-5 (as negative controls) 
transfected HEK cells. Such experiments could help to find out whether low 
dsRNA concentrations are required for HRV RNA induced RIG-I activation or not. 
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Furthermore, transfections with replication deficient HRV RNA would also better 
mimick the situation in DC, where no HRV replication occurs. 
In addition, it will be necessary to perform knock down experiments of the 
candidate VPRR for HRV14 in DC as a proof of principle. It would also be 
interesting to find out which parts of the genomic RNA are detected by DC. This 
could be tested by transfecting selected in vitro transcribed stretches of RNA into 
DC and HEK reporter cells. 
Taken together, this study shows that the ssvRNA of HRV is only a semi-danger 
signal for DC: The ssvRNA of HRV is specifically recognized by DC, causing a 
strong IFN response. However, ssvRNA fails to induce NFκB activation, which is 
required for proper maturation induction. In addition, maturation markers are 
absent, proinflammatory cytokines are not produced and HRV ssvRNA fails to 
induce an increased T-cell stimulatory capacity in an allo-MLR. 
The results from the HEK luciferase reporter assays suggest that the ssvRNA 
activates RIG-I in HEK cells. Upcoming evaluation of these data in DC will help to 
clarify HRV recognition processes and VPRR signaling in DC. 
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5. Material & Methods 
5.1. Monoclonal antibodies  
 
Specificity Clone Isotype source 
B7-H1 DF272 IgG1 Otto Majdic, Institute of 
Immunology, Vienna 
Calf intestine alkaline 
phosphatase  
VIAP IgG1 Otto Majdic 
CD1a VIT6b IgG1 Otto Majdic 
CD11b VIM12 IgG1 Otto Majdic 
CD14 MEM18 /VIM13 IgG1 / IgM Otto Majdic 
CD16 3G8 IgG1 Caltag, Burlingham, CA 
CD19 BU12 IgG1 G. Moldenhauer, Heidelberg, 
Germany 
CD33 4D3 IgG2 Otto Majdic 
CD40 G28-5 IgG1 ATCC, Rockville, ML 
CD54 5-341 IgG2a Otto Majdic 
CD80 7-480 IgG1 Otto Majdic 
CD83 HB15 IgG2b Caltag 
CD86 BU63 IgG1 Caltag 
CD169 (Sialoadhesin) 7-239 IgG1 Otto Majdic 
MHCI W6/32 IgG2a ATCC  
MHCII CLII-1.47 IgG2a Otto Majdic 
MxA 383-7D4 IgG1 Otto Majdic 
Table 2: Monoclonal antibodies (mouse) used in this study 
5.2. Isolation of peripheral blood mononuclear cells (PBMC) 
 
Heparin-medium: 500ml RPMI 1640 (+ 10% FCS +100U/ml penicillin + 100ug/ml 
streptamycin and 2mM L-glutamine) + 10 U/ml Heparin (stock: 5000U/ml, Baxter, 
Vienna) 
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MACS-buffer: 1000 ml 1x PBS def. + 25 ml HSA (stock: 20%, Centeon, Vienna) 
+ 10 ml EDTA (stock: 0,5M; Gibco, Invitrogen GmbH, Lofer, Austria); sterile 
filtered 
 
Peripheral blood mononuclear cells were separated from whole blood of healthy 
donors by density gradient centrifugation using Ficoll-Plaque (Amersham, Little 
Chalfont, UK). Blood was diluted 1:2 to 1:3 with heparin-medium. For density 
gradient centrifugation a layer of heparinized blood was carefully pipetted onto 15 
ml of Ficoll-Plaque. The cells were spun 30 minutes at 1750 without brake. After 
centrifugation granulocytes and erythrocytes gathered at the bottom of the tube, 
whereas PBMC formed a ring in the interphase. This ring was transferred into a 
new tube and spun down (5 minutes, 1750 rpm). The pelleted cells were washed 
twice with MACS-buffer: The pellet was resuspended in a few ml of buffer, filled 
up to 50 ml and spun down (5 minutes, 1750 rpm). After discarding the 
supernatant, the washing step was repeated. The number of PBMC was 
determined by the Coulter particle count & size analyzer (Beckman Coulter, Inc., 
Fullerton, CA) and the cells were used for isolating monocytes and T-cells. 
5.3. Magnetic cell sorting (MACS) 
 
Magnetic cell sorting (MACS) is a method for selective enrichment or depletion of 
cells expressing a surface protein distinct for their cell type. For this purpose, 
cells can be labelled with biotin-conjugated antibodies directed against the 
specific molecule. These labelled cells can be targeted by a secondary antibody 
directed against the biotin residues on the primary antibody. Since the secondary 
antibody is coupled to paramagnetic beads, specific cells in a mixture can be 
selectively retained in the iron mesh of the column once a strong magnetic field is 
applied. While nonlabelled cells pass through the column, retained cells may be 
eluted by removing the magnetic field. 
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Material: 
Straptavidin-Microbeads 
Magnetic cell separator VarioMACS 
Separation column CS 
(all from Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) 
5.3.1. Isolation of monocytes from PBMC 
 
Monocytes were positively selected by MACS from PBMCs. For the selection the 
monocyte marker CD14 was used. 
Around 1x109 PBMCs were used for one MACS separation column. The cells 
were resuspended in 750 µl MACS-buffer and 250 µl biotinylated anti-CD14 mAb 
(VIM13 and MEM18, both 15 µg/ml, Otto Majdic) were added (15 min, 4° C). 
After washing twice with MACS-buffer the pellet was resuspended in 750 µl 
MACS-buffer and 250 µl streptavidin-microbeads were added (15 min, 4° C). 
To wash the column, it was assembled and placed in the magnetic field. Buffer 
was injected through the 3-way stopcock using the side syringe. The cell 
suspension was pressed through a 70 µm strainer and loaded onto the column. 
Buffer was added untill 40 ml had passed through. A 0,8 µm needle was used to 
control the flow rate. This first fraction contained T-, B- and NK-cells. For the 
second fraction the column was removed from the magnetic field and the buffer 
was added in 10 ml portions alternating through the side syringe or loaded on the 
top of the column. After each addition step the column was put back into the 
magnetic field and about 10 ml were let run through. For this fraction a 0,9 µm 
needle was used. The steps were repeated until 50 ml had passed through.  
The third and monocyte containing fraction was collected after removal of the 
column from the magnetic field. Buffer was filled several times into the reservoir 
of the column. After each step the liquid was taken out through the lateral valve 
using a syringe. These steps were repeated until a volume of 40 ml had been 
collected. The number of monocytes was determined after centrifugation (5 min, 
1750 rpm) and resuspension. 
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The purity (> 95%) of the isolated monocytes was controlled by 
immunofluorescence analysis. Double stainings for surface markers were 
performed with the directly labelled antibodies CD4-PE / CD3-FITC, CD8-PE / 
CD3-FITC, CD19-PE / CD3-FITC, CD56-PE / CD3-FITC, HLA-DR / CD3-FITC, 
HLA I-FITC, CD14-PE / HLA-D-FITC. 
5.3.2. Isolation of T-cells  
 
The first fraction of the monocyte isolation protocol was used for the selection of 
T-cells by depletion of CD11b (mAb: LM2, 15 µg/ml), CD14 (MEM18, 15 µg/ml), 
CD16 (3G8, 15 µg/ml), CD19 (BU12, 15 µg/ml), CD33 (CD33-4D3, 30 µg/ml) and 
MHC II (VID1, 15 µg/ml) positive cells.  
After centrifugation (5 min, 1750 rpm), the cells were resuspended in 750 µl 
MACS-buffer and 250 µl biotinylated mAb-mix (anti-CD11b, CD14, CD16, CD19, 
CD33 and MHCII mAb) were added (15 min, 4° C). After washing twice with 
MACS-buffer, the pellet was resuspended in 750 µl MACS-buffer and 250 µl 
streptavidin-microbeads were added (15 min, 4° C). 
To wash the column, it was assembled and placed in the magnetic field. Buffer 
was injected through the 3-way stopcock using the side syringe. The cell 
suspension was pressed through a 70 µm strainer and loaded onto the column. 
Buffer was added until 50 ml had passed through. For the negative depletion, a 
0,7 µm needle was used to control the flow rate. 
The collected fraction was spun down and the cells were counted. The purity 
(>95%) was controlled by immunofluorescence analysis. Double stainings for 
surface markers were performed with the directly labelled antibodies CD4-PE / 
CD3-FITC, CD8-PE / CD3-FITC, CD19-PE / CD3-FITC, CD56-PE / CD3-FITC, 
HLA-DR / CD3-FITC, HLA I-FITC, CD14-PE / HLA-D-FITC. 
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5.4. Generation of md-DC 
 
md-DC were generated by culturing purified peripheral blood CD14+ monocytes 
for 5-7 days in RPMI1640 (Gibco, Invitrogen GmbH, Lofer, Austria) 
supplemented with 10% FCS (Sigma-Aldrich, St. Louise, MO), 2 mM L-glutamine 
(Gibco, Invitrogen GmbH, Lofer, Austria), 100 U/ml penicillin, 100 U/ml 
streptamycin (Sigma-Aldrich, St. Louise, MO), 50 ng/ml GM-CSF and 100 U/ml 
IL-4. Cells were incubated at 37° C, 5 % CO2. 
5.5. Freezing & thawing of cells 
 
Mammalian cells can be stored in liquid nitrogen for prolonged periods of time 
with minimal loss of viability in subsequent cell culture. For that purpose, cells 
were spun down, counted and resuspended in freezing medium (RPMI1640 
supplemented with 20% FCS, 100U/ml penicillin, 100 µg/ml streptamycin, 2mM 
L-glutamine and 10% DMSO) to a concentration between 1 – 5x 107 cells/ml. 1 
ml aliquots were filled into cryotubes (Nalgen Nunc Internation, Roskilde, 
Denmark) and stored overnight at -80° C in a freezing box filled with isopropanol 
prior to transfer to liquid nitrogen. 
For thawing, frozen cells were warmed with lukewarm tap-water until a clump of 
frozen cells was left in the tube. After 5 minutes, the cell suspension was 
transferred to a 20 ml tube and droplets of supplemented cell culture medium 
where added in an interval of 1 min: Starting with 5 drops at 0`, 10 drops at 1`etc.  
up to 5 minutes. After two washing steps, the cell number was determined by the 
Coulter particle count & size analyzer (Beckman Coulter, Inc., Fullerton, CA). 
5.6. Stimulation of DC 
 
DC were cultured at a density of 1x106 /ml (most experiments) or 2x106 /1.5ml 
(for RNA isolation) in supplemented RPMI (+10% FCS +100U/ml penicillin + 100 
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µg/ml streptamycin and 2mM L-glutamine). Stimulations were carried out at the 
indicated concentrations (see table). 
 
Stimulus Concentration /ml Source 
LPS 0,1-1 µg Sigma-Aldrich 
pI:C 2 µg Sigma-Aldrich 
R-848 2 µg Alexis Biochemicals 
HRV14 5 TCID50 Joachim Seipelt 
HRV2 5 TCID50 Joachim Seipelt 
pI:C + 
Lipofectamine2000 
0,2 µg + 0,5 µl Sigma-Aldrich 
HRV14 RNA + 
Lipofectamine2000 
0,0172 / 0,086 / 0,43 pmol +  
0,1 / 0,5 / 2,5µl 
In vitro transcription 
HRV2 RNA+ 
Lipofectamine2000 
0,0172 / 0,086 / 0,43 pmol +  
0,1 / 0,5 / 2,5 µl 
In vitro transcription 
Control RNA + 
Lipofectamine2000 
0,0172 / 0,086 / 0,43 pmol +   
0,025 / 0,125 / 0,625 µl 
In vitro transcription 
Lipofectamine2000 0,1 / 0,5 / 2,5µl  invitrogen 
Table 3: Overview about reagents used for DC stimulation 
5.7. Virus preparations 
 
Virus preparations were obtained from the lab of Prof. Joachim Seipelt. Virus 
stocks prepared in Hela Ohio cells (as described in 96) were further purified using 
sucrose gradients. Virus was pelleted by centrifugation at 100 000 g for 2 h and 
resuspended in small volume „virus buffer“ (50 mM Tris (pH 7,5), 2 mM MgCl2). It 
was then treated with DNase I (5 mg/ml, Fermentas, St. Leon-Rot, Germany) and 
RNase A (5 mg/ml, Fermentas, St. Leon-Rot, Germany) for 10 min at RT and 
further digested with trypsin (0,5 mg/ml, Dipro) for 5 min at 37° C. After addition 
of N-laurylsarcosin (0,1 %, Schuchardt, Munich, Germany) digestion was 
continued overnight at 4° C. After removal of the low-speed centrifugation, the 
sample was centrifuged on a sucrose gradient (7,5 – 45 % sucrose in virus 
buffer) for 2 h at 155 000 g. Virus-containing fractions are visible as a turbid band 
in the middle of the gradient and were collected with a syringe. Virus was 
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concentrated by pelleting and resuspension in virus buffer. Virus stocks had a 
concentration of 1,61 x109 (HRV14) and 6 x108 (HRV2) / TCID50 /ml and were 
stored at -80° C until use. Virus stocks were tested for LPS contaminations via 
FACS analysis of maturation markers after DC stimulation with virus or heat-
inactivated virus and compared to LPS and heat-inactivated LPS treated DC. 
5.8. Measurement of cytokines from culture supernatants 
 
The Fluorokine® MultiAnalyte Profiling (MAP) system (R&D Systems Inc., 
Minneapolis, MN), provides a tool to simultaneously measure multiple cytokines 
in a single sample. Analyte-specific antibodies are pre-coated onto color-coded 
beads. Standards and samples are pipetted into the wells and analytes of 
interest are bound by the immobilized antibodies. After washing away any 
unbound substances, biotinylated antibodies specific for the analytes of interest 
are added. Following a wash, captured analyte is detected using streptavidin-
phycoerythrin  (S-PE). The Luminex100 analyzer is a dual laser, flow-based, 
sorting and detection platform. One laser is bead-specific and determines which 
cytokine is being detected. The other laser determines the magnitude of PE-
derived signal, which is in direct proportion to the amount of analyte bound. 
Supernatants from various experiments after 48h of DC stimulation were 
measured via the Luminex100 System for their content of IL-10, IL-12p40, IL-6 
and TNFα. 
5.9. IFNα enzyme-linked immunosorbent assay (ELISA) 
 
IFNα concentrations in the supernatants of stimulated DC (48h) were determined 
by human IFN-α ELISA kit (PBL InterferonSource, NJ). 
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5.10. Linearization of DNA templates used for in vitro 
transcription 
 
T7 Polymerase in vitro transcription plasmids encoding full-lenght genomic 
HRV14 / HRV2 RNA including the poly A tail (plasmids provided by Prof. 
Joachim Seipelt) were linearized by restriction enzyme digestion. For this 
purpose, 10 µg of DNA from maxiprep (Qiagen, Germantown, MD) were 
incubated with 2 µl BSA 100x, 5 µl appropiate 10x reaction buffer  (both New 
England Biolabs, Frankfurt am Main, Germany), either 3 µl MluI (HRV2, 10 
000U/ml, New England Biolabs Frankfurt am Main, Germany,) or 3 µl KpnI 
(HRV14, 10 U/µl, Fermentas, St. Leon-Rot, Germany) and nuclease free water 
(Gibco, Invitrogen GmbH Lofer, Austria) in a total volume of 50 µl (overnight, 37° 
C). 
Successful linearization was checked by agarose gel electrophoresis by 
comparing linearized and circular templates (1% agarose in 1xTAE, 90 V, 1,5 h). 
The linearization reaction was stopped by adding 1/10 5M NH4 acetate stop 
solution and 2 volumes of 96% ethanol (1h, -20 C). The pelleted DNA (40 min, 
13000 rpm, 4° C) was washed with 200 µl 70% ethanol and centrifuged once 
more (15 min, 13 000 rpm, 4° C). The dried pellets (20 min, RT) were 
resuspended in 20 µl nuclease free water (all reagents except ethanol provided 
with MEGAscript High Yield Transcription Kit, Ambion, Austin, TX). 
5.11. RNA preparation by in vitro transcription 
 
To generate high amounts of viral RNA the MEGAscript High Yield Transcription 
Kit (Ambion, Austin, TX) was used: 1 µg of linear DNA template was mixed with 8 
µl of NTP mix, 2 µl of 10x reaction buffer, 2 µl T7 polymerase enzyme mix and 7 
µl of nuclease free water (4h, 37° C). The DNA template was digested by 
addition of 1 µl of TURBO DNase (15min, 37° C). The in vitro transcribed RNA 
was precipitated by adding 30 µl of LiCl precipitation solution and 30 µl of 
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nuclease free water (30 min, -20° C). After centrifugation (15 min, 13000 rpm, 4° 
C) the RNA was washed with 70% ethanol. Pelleted (15min, 13000 rpm, 4° C) 
and dried (5 min, RT) RNA was resuspended in 50 µl nuclease free water. RNA 
concentrations were determined at 260 nm with a BioPhotometer (Eppendorf, 
Germany). 
To obtain dephosphorylated RNA part of the RNA was treated with 1 U / 20 pmol 
RNA of calf intestine alkaline phosphatase (30min, 37° C, Fermentas, St. Leon-
Rot, Germany). Purified (de-) / phosphorylated RNA (RNeasy Mini Kit, Qiagen, 
Germantown, MD) was eluted with 30 µl of nuclease free water and the RNA 
concentration was determined once more. RNA was stored in aliquots at -80° C 
until use. Size, integrity and purity of RNA was determined by agarose 
electrophoresis (1% agarose in 1xTAE, 90V, 2h) after denaturing RNA in 5x RNA 
loading buffer (16 µl saturated aqueous bromophenol blue solution, 80 µl 500mM 
EDTA pH 8.0, 720 µl 37% formaldehyde, 2 ml 100% glycerol, 3,084 ml 
formamide and 4 ml 10x FA gel buffer containing 200 mM MOPS, 50 mM sodium 
acetate and 10 mM EDTA pH 7.0) at 65° C for 3-5 minutes. 
As a control, 1µg of linearized control template (provided with the kit) encoding 
the 1,89 kb Xenopus elongation factor 1α gene was included in each in vitro 
transcription reaction and part of it was also dephosphorylated as described 
above. 
5.12. Isolation of total cellular RNA 
 
Total cellular RNA / viral RNA was isolated using TRI reagent (Sigma, St. Louis, 
MO). Up to 1x 107 pelleted cells or 200 µl of viral suspension were resuspended 
in 1ml TRI reagent (5min, RT; optional: -20° C until need). To remove proteins 
200 µl of chloroform were added, vortexed (15 s) and incubated for 2-15 min at 
RT. After centrifugation (15 min, 13 000 rpm, 4° C) the aqueous phase was 
transferred into a new tube and mixed with 500 µl isopropanol. After 5-10 min at 
RT the samples were centrifuged (10 min, 13 000 rpm, 4° C) and the pellets were 
washed with 1 ml 75% ethanol. After a final centrifugation (10 min, 13 000rpm, 4° 
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C) the RNA pellet was air-dried for 5-10 min at RT and resuspended in 30 µl 
(viral RNA) or 12 µl (for cDNA) nuclease free water (Gibco, Invitrogen GmbH, 
Lofer, Austria). 
5.13. Generation of cDNA 
 
To generate cDNA 800-1000 ng of isolated total RNA from stimulated cells was 
reverse transcribed with Revert Aid MuLV-RT (Fermentas, St. Leon-Rot, 
Germany) using Oligo (dT)18 primers according to the manufacturer`s protocol. 
800-1000 ng of RNA were mixed with 1 µg oligo (dT)18 primers and NFW was 
added up to 11µl. After incubation at 70° C for 5 minutes the samples were 
chilled on ice. To each reaction 4 µl of 5x MuLV-RT buffer, 2ul dNTP mix (10mM 
each), 0,5 µl RiboLock RNase Inhibitor (20 U), 1 µl Revert Aid MuLV reverse 
transcriptase (200 U), and NFW to a final volume of 20 µl were added. The 
mixture was incubated for 5 minutes at 37° C, followed by incubation at 42° C for 
60 minutes. cDNA was stored at -20° C until use. 
5.14. Real-Time PCR (RT-PCR) 
 
Quantitative Real-Time PCR (RT-PCR) was performed by the Mx3005P QPCR 
system (Stratagene, La Jolla, CA) using SYBR Green detection. In all assays, 
cDNA was amplified using a standard program (2 min at 50° C, 10 min at 95° C, 
40 cycles of 15 sec at 95° / 15 sec at 60° C / 30 sec at 72° C, 1 min at 95° C, 30 
sec at 54° C and 1 min at 95° C). 
Each well of the MicroAmp 96well plate (Applied Biosystems, Foster City, CA) 
was loaded with 0,34 µl cDNA, 1 µl primer mix (5 mM each primer), 5 µl Sybr 
Green Power PCR Mix (Applied Biosystems, Foster City, CA) and 3,66 µl 
nuclease free water (Gibco, Invitrogen GmbH, Lofer, Austria) to give a total 
volume of 10 µl. Relative quantification of target gene expression was performed 
by the MxPro QPCR software from Stratagene (housekeeping gene: G3DPH). 
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The testing of primer specificity included melting point analysis and agarose gel 
eletrophoresis of the PCR products. 
 
Primer sequences: 
IFN-beta:  
Forward: 5`-TGCATTACCTGAAGGCCAAGG-3` 
Reverse: 5`-GCAATTGTCCAGTCCCAGAGG-3` 
HRV14: 
Forward: 5`-GGCGCCATATCCAATGGTGT-3` 
Reverse: 5`-TCCACCTGATCGAACGTCCA-3` 
5.15. Electrophoretic mobility shift assay (EMSA) 
 
EMSA were performed by Karl Stuhlmeier at the Franz Joseph Spital, Vienna.113 
For this purpose, 5x106 md-DC were mock-treated, stimulated with 100ng/ml 
LPS  for 30minutes or 5 TCID50/cell HRV14 for 30 minutes, 1h, 3h, 5h, 7h and 
9h. Stimulation was stopped by adding ice-cold PBS. Cells were transported on 
ice. 
5.16. Flow cytometry 
 
In a flow cytometer, single cells move past the excitation source and the light 
hitting the cells is either scattered or absorbed and then re-emitted 
(fluorescence). This scattered or re-emitted light is collected by a detector. 
Scattered light is the consequence of a light beam making contact with a cell, 
resulting in either reflected or refracted light reaching the detector. The pattern of 
light scattering is dependent on cell size and shape, giving relative measures of 
these cellular characteristics as cells flow through the beam. This can be quite 
useful, as cells can be sorted on the basis of size or shape to different collection 
tubes using a technique called electrostatic deflection, which employs charged 
plates to change the path of the cell. Fluorescence-based detection depends on 
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the absorption of light by the cell and the subsequent re-emission of this light at a 
different wave-lenght. 
Flow cytometers make use of this technology by employing filters to block the 
original light source from reaching the detector, while the fluorescence emission 
is allowed through the detector, which allows only a very low background of stray 
light to reach a detector. In flow cytometry experiments, fluorescence is often 
achieved by the deliberate labelling of a cellular component using a fluorescent 
marker, usually a type of dye, covalently bound to an antibody. These dyes emit 
light only if light of the appropriate wavelenght (specified by the frequency of the 
laser) hits them, causing the emission of secondary light at a different 
wavelenght. Detection of the second wavelenght is used as a measure of the 
presence of the antigen recognized by the antibody on the cell. 
5.16.1. Immunofluorescence of surface proteins 
 
Binding of mAbs to Fcγ -receptors was blocked by incubation of cells with human 
immunoglobin (Beriglobin). As a negative control VIAP, a non-binding calf 
intestine alkaline phosphatase specific antibody was used. For secondary 
labelling, we applied an oregon green-conjugated goat anit-mouse antibody. 
Dead cells were excluded from the analysis by staining with propidium iodide. 
 
PBS/BSA: 1x PBS def. + 1% BSA 
Beriglobin (Aventis Behring GmbH, Vienna) diluted 1:8 in PBS/BSA to final 
concentration of 20mg/ml 
Primary antibodies: 20 µg/ml 
Secondary antibodies: oregon green-conjugated goat anti-mouse IgG (Molecular 
Probes, Eugene, Oregon), 20 µg/ml in PBS/BSA 
Propidium iodide: 1ug/ml in PBS/BSA 
 
Pelleted cells (5x105/Assay, 5min, 1750 rpm) were resuspended in 50 µl 
beriglobin/assay and kept on ice for 20min. 50 µl of cell suspension were added 
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to 20 µl primary antibody in micronic-tubes (after mixing 30min at 4° C). Each 
assay was washed twice with PBS/BSA (5 min, 1750 rpm). Cells were incubated 
with 20 µl of secondary antibody/assay (30min, 4° C). 
After washing cells twice with PBS/BSA, dead cells were labeled with propidium 
iodide (1:100) and mixed with 25-50 µl sheath fluid (BD FACS Flow, BD 
Bioscience, San Jose, CA). 
The tubes were kept at 4° C in the dark until analyis by flow cytometry using the 
FACScalibur Flow Cytometer (Becton Dickinson, Palo Alto, CA). 
5.16.2. Immunofluorescense of cytoplasmic proteins 
 
Fixation medium  
Permeabilization medium 
Both from (Bio Research GmbH, An der Grub, Kaumberg, Austria) 
 
Pelleted cells (5x105/Assay, 5min, 1750 rpm) were resuspended in 50 µl 
beriglobin/assay and kept on ice for 20min. 50 µl of cell suspension were added 
to 50 µl of fixation medium (20 min, RT). After washing twice (5min, 1750 rpm) 
cells were incubated with 20 µl primary antibody (20 µg/ml) and 50 µl 
permeabilization medium in micronic-tubes (after mixing 20min at RT). Each 
assay was washed twice with PBS/BSA (5 min, 1750 rpm). Cells were incubated 
with 20 µl of secondary antibody (20 µg/ml)/assay (20min, RT). 
After washing cells twice with PBS/BSA they were mixed with 25-50 µl sheath 
fluid (BD FACS Flow, BD Bioscience, San Jose, CA). 
No propidium iodide was added prior analysis by flow cytometry using the 
FACScalibur Flow Cytometer (Becton Dickinson, Palo Alto, CA). 
5.17. HEK Luciferase Reporter Assay 
 
For the HEK Luciferase Reporter Assay a luciferase reporter plasmid was 
transfected into HEK293 cells along with an expression plasmid for a given viral 
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VPRR. Production of the reporter protein luciferase is only induced upon VPRR 
activation which causes IFN production and NFκB activation required for reporter 
gene expression. The quantification of the reporter protein activity after 
stimulation, normalized to mock treated cells, allows to identify stimuli which are 
specifically recognized by certain VPRR. 
HEK293 cells were seeded in 96 flat bottom well plates at 100 000 cells / well in 
100 µl supplemented IMDM (IMDM, 10% FCS +100 U/ml penicillin + 100 µg/ml 
streptamycin and 2 mM L-glutamine). 24 hours later, cells were transiently 
transfected by CaCl2 transfection. For this purpose, 1 µg ß-galactosidase (ß-gal) 
plasmid, 1 µg VPRR plasmid and 0,04 – 0,2 µg reporter plasmid were mixed with 
nuclease free water to give a final volume of 45 µl. After incubation with 5 µl 2,5M 
CaCl2 (5min, RT), 50 µl of 2x HBS buffer pH 6.95 were added during vortexing. 
After 1 minute rest, 10 µl of the stock were pipetted to each well.  
20 hours after transfection, medium was changed to supplemented IMDM lacking 
antibiotics. Stimulations with Transfectin (BIORAD, Hercules, CA) complexed 
pI:C (1 ug) / HRV14 or control RNA (between 0,0172 – 1,68 pmol) were carried 
out for 12-18 hours. After stimulation the medium was carefully aspirated and 
cells were lysed with 25 µl / well 1x CCLR lysisbuffer (Promega, Madison, WI) for 
1 minute. Plates were stored at -20° C overnight or at -80° C for a maximum of 3 
days.  
Luciferase activity was asssesed by transfering 10 µl of lysate to 96 well Microlite 
1+ plates and measuring light emission after addition of 50 µl / well luciferase 
assay reagent (Promega, Madison, Wisconsin) using the Labsystems 
Luminoskan RS luminometer (lag time 2 sec, total time 12 sec, Labsystems, 
Finland). 
ß-gal activity, as a measure of transfection efficiency, was assesed by addition of 
100 µl ß-gal substrate solution (0,1 M NaPO4 pH 7.5, 1 mM MgCl2, 45 mM ß-
mercaptoethanol, 1 mg/ml ONPG) / well to the remaining lysate. After 5-10 
minutes incubation (37 C, 5% CO2) the absorbance at 405 nm compared to 650 
nm was measured using the THERMOmax microplate reader (Molecular 
Devices, Toronto, Canada). 
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Insert Plasmid Supplied by  
flagRIG-I full 
lenght 
pEF-BOS Takashi Fujita Laboratory of molecular genetics 
Kyoto University (Japan) 
Luciferase pISRE-TA-Luc  Promega Madison, Wisconsin 
Luciferase p NFκB -TA-Luc  Promega Madison, Wisconsin 
Table 4: Overview about plasmids used for the HEK luciferase reporter assay 
 
5.18. Preparation of cell lysates 
 
For preparing cell lysates 1x106 DC were pelleted (3min, 3000rpm) and 
resuspended in 75 µl 2x Laemmli buffer containing 50 µl ß-mercaptoethanol / ml 
(both BIORAD, Hercules, CA). Samples were frozen in liquid nitrogen and 
transfered to -80° C for long term storage. 
The samples were sonicated (15 s) and denatured (5 min, 95° C) before SDS-
PAGE. 
5.19. SDS-polyacrylamide electrophoresis (SDS-PAGE) 
 
Under denaturing conditions SDS masks the charged residues of proteins. SDS-
PAGE therefore allows the eletrophoretic separation of proteins according to their 
size. Protein size is determined by using a protein standard of defined molecular 
weights.  
The gel caster (Hoefer Scientific Instruments, San Francisco, CA) was prepared 
by assembling ethanol-cleaned glass / aluminium oxide plates and spacers. The 
running gel was prepared, cast up to 2 cm below the upper edge of the glass 
plate and covered with 96% ethanol (20min). After removing residual ethanol, the 
stacking gel was added and a comb carefully placed on top (20min). 
After successful polymerization the chambers in the gel apparatus (Hoefer 
Scientific Instruments, San Francisco, CA)  were filled with 1x running buffer. 
Samples (10-12 µl) were loaded along with 5 µl SeeBlue Plus 2 Prestained 
Standard (Invitrogen GmbH, Lofer, Austria). Empty slots were filled with Laemmli 
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buffer. Gels were run constant at 60 V until the running gel was reached. Then 
the voltage was set to 120 V till proper separation. 
 
Running gel (10%, for 2 gels):  
4,8 ml aqua dest.   
3 ml Tris HCl 1.5 M pH 8.8 
4 ml Rotiphorese Gel 30 solution (Roth, Karlsruhe, Germany) 
100 µl 10% SDS 
100 µl 10% APS 
8 µl TEMED 
 
Stacking gel (4%, for 2 gels): 
2 ml aqua dest. 
840 µl Tris-HCl 0,5 M pH 6.8 
400 µl Rotiphorese Gel 30 solution (Roth, Karlsruhe, Germany) 
35 µl 10% SDS 
35 µl 10% APS 
4 µl TEMED 
5.20. Westernblot analysis 
 
Blotting buffer (1x) 
100 ml stock (25 mM Tris, 192 mM glycine) 
100 ml methanol 
800 ml aqua dest. 
 
PBS-T (wash solution): 
1x PBS + 0,05% Tween-20 
 
Blocking solution: 
5% milk in PBS-T 
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After electrophoresis, SDS-gels were separated from the glass plates and 
marked at one end. The PVDF membrane (Immobilon-P, 0.45 µm, Millipore, 
Billerica, MA) and filterpapers (blotting paper 703, VWR, Darmstadt, Germany) 
were cut to fit the size of the gel. The PVDF membrane was shaken with 
methanol (1 min) and equilibrated together with the gel in blotting buffer (5 min). 
Finally the sandwich was assembled by putting membrane and gel between 3 
buffer soaked filter papers at each side. The proteins were transfered onto the 
membrane at a constant voltage (15 V, 1h) using the Semi-Phor blotting 
apparatus (Hoefer Scientic Instruments, San Francisco, CA). 
To prevent antibodies from unspecific binding to the membrane, it was shaken 
with blocking solution (1 h, 4° C). Incubations with the primary antibody were 
carried out in a 50 ml falcon tube (Sarstedt, Nümbrecht, Germany) with a 
minimum of 4 ml antibody solution diluted in blocking solution (7 rpm, overnight, 
4° C). After washing (3x 10 min) membranes were incubated with the secondary 
HRP conjugated antibody dilution (blocking buffer) in a 50 ml falcon tube (7 rpm, 
1 h, 4° C). Before ECL, membranes were given a final wash (3x 10min). 
 
Specificity Clone Isotype Species Dilution Company 
IkBα Sc-371 IgG Rabbit 1:1000 Santa Cruz Biotech 
p38 - IgG Rabbit 1:1000 Cell Signaling 
Rabbit IgG - IgG-HRP Goat 1:2000 Dako 
Table 5: Polyclonal antibodies used for westernblot analysis 
5.20.1. Development of blots by enhanced chemiluminescence (ECL) 
 
ECL solution (200 ml, stored in the dark): 
20 ml 1 M Tris pH 8.8 
1 500 µl aliquot p-coumaric acid (340 mg in 26 ml DMSO, Sigma-Aldrich, St. 
Louise, MO) 
1 1 ml aliquot Luminol (2,26 g in 51 ml DMSO, Fluka, Sigma-Aldrich, St. Louise, 
MO) 
Material & Methods 
  
 
180 ml aqua dest. 
 
For ECL, membranes were incubated with ECL solution mixed with 3 µl / ml 3% 
hydrogen peroxide for 1 minute, placed between two plastic overhead sheets, 
covered with a Kodak Biomax XAR film (Sigma-Aldrich, St. Louise, MO) and 
placed into a film casette. After exposure from 1 sec up to 1 hour specific bands 
were visible on the film where light had been emitted during HRP enzyme activity 
after developing the film in a developing machine. 
5.20.2. Stripping of membranes for reuse 
 
After ECL, membranes were either stored at 4° C or washed 3x 5min with PBS-T 
to remove ECL solution. To allow incubation with antibodies detecting proteins of 
similiar size, bound antibodies were removed by incubation of the membranes in 
40 ml stripping buffer (6,25 ml 1 M Tris pH 6.8, 20 ml 10% SDS up to 100 ml with 
aqua dest. + 704 µl ß-mercaptoethanol) at 65° C for 20min. 
To remove ß-mercaptoethanol, the membranes were washed 20x with dH20 and 
finally blocked with blocking solution (shaking, 1 h, 4° C). 
5.21. Allo mixed leukocyte reaction (Allo MLR) 
 
The MLR is a system to simulate a graft-versus-host reaction: lymphocytes from 
a potential donor are mixed with stimulator cells from a potential recipient. If the 
two cell populations are not compatible in their MHC (allogeneic), proliferation of 
the T-cells occurs. This expansion is determined by measuring the methyl-3H-
thymidine incorporation into the DNA. 
Graded numbers of DC (333, 1111, 3333 and 10000 cells) were mixed with 105 
responder T-cells from a different donor in supplemented RPMI 1640 in 96 well 
round bottom plates under standardized culture conditions (37° C, 5% CO2, 
humidified atmosphere). On day 5, 25 µl of 1:20 diluted methyl-3H-thymidine (1 
µCi / well) (ICN Pharmaceuticals Inc., Irvine, CA) was added to the cells. After 18 
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h incubation, the cells were lysed and their DNA collected on filter-plates (Perkin 
Elmer, Wellesley, MA). To each well on dried plates (37° C, 1 h) 25 µl of 
microscint scintillation mix (Packard, Meriden, Conneticut) was added. 
Radioactive emission was quantified on a Packard microplate scintillation counter 
(Packard, Meriden, Conneticut). For each setting triplicates were used. 
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